AcuCort

Trademark protection is strategically important in AcuCort’s ongoing commercialisation phase.

– The fact that Zeqmelit® is now also protected as a trademark in Canada is an important step in our international expansion. It strengthens our ability to establish the product in new markets and is part of our strategic work to build a strong and protected global brand, says AcuCort’s CEO Jonas Jönmark.

The registration is valid in accordance with the dates of the International Registration and will be renewed in conjunction with the renewal of the International Registration on 9 January 2033.
Zeqmelit® has been registered as a trademark in all member states of the European Union, as well as in Norway, the United Kingdom, Switzerland, Australia, India, Israel, China, Japan, the United States, and now also in Canada.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.